Fenwick & West represented Solta Medical, Inc. (NASDAQ: SLTM), designer, developer, manufacturer and marketer of energy-based medical device systems for aesthetic applications, in its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. Valeant will acquire all of the outstanding common stock of Solta Medical for $2.92 per share in cash, which represents a 40% premium to Solta Medical’s closing price on December 13, 2013, the last trading day prior to the announcement, or an approximate aggregate value of $250 million. The transaction is expected to close in the first quarter of 2014.
The Fenwick transaction team included corporate partners Daniel Winnike and Kris Withrow; executive compensation and employee benefits partner Blake Martell; intellectual property and antitrust partner Mark Ostrau; and tax partner Ronald Schrotenboer. The deal team also included corporate associates Ken Myers, Niki Fang, Scott Behar, Kristin O’Hanlon and Julia Forbess; executive compensation and employee benefits associate Adriana Sherwood; technology transactions associate Claire O’Callaghan; and foreign lawyer clerk Guilherme Potenza.
More information about Solta Medical’s acquisition by Valeant Pharmaceuticals is available through the announcement on Solta Medical’s website.